Table 1.

Literature review of the case reports documenting adverse cutaneous reactions as a result of a COVID‐19 vaccine ³ , ⁴ , ⁵ , ⁶ , ⁷ , ⁸ , ⁹

Age	Gender	Comorbidities	Vaccine	Presentation	Onset	Treatment	Outcome	Reference
55	Male	Nil of note	Pfizer (1st dose)	Maculopapular rash Face, Trunk, Upper extremities and Thighs	3 h	Topical steroids	Resolution within days Did not take 2nd dose	3
20s	Female	Alopecia	Pfizer (1st dose)	Pityriasis rosea‐like eruptions Trunk and Proximal extremities	2 days	Topical steroids	Resolution after 2 weeks	4
40s	Male	Nil of note	Pfizer (2nd dose)	Pityriasis rosea‐like eruptions Trunk and Proximal extremities	2 days	Doxycycline and Bilastine	Resolution after 3 weeks	4
60	Male	DM, HTN on Tenegliptin, Metformin, Amlodipine	Unknown (1st dose)	Steven Johnson Syndrome Extensive involvement with oral lesions	3 days	Ciclosporin	Resolution after 7 days Did not take 2nd dose	5
30	Male	Nil of note	Pfizer (both doses)	Pruritic erythematous morbilliform eruption	2 days†	Nil	Resolution after 24 h	6
83	Female	HTN Hypothyroidism Breast cancer on Palbociclib, Letrozole, Vitamin D	Johnson & Johnson (single dose)	Pruritic annular patches with central clearing Trunk and Axilla	2 days	Antihistamines and Topical steroids	Resolution after 2 weeks	7
56	Female	Lichen planus	Pfizer (2nd dose)	Lichen planus Extensive involvement	2 days	Topical steroids	N/A	8
26	Female	Nil of note	Pfizer (both doses)	Fixed drug eruption Near injection site	14 days‡	N/A	N/A	9

Data documented in the study by McMahon et al. are excluded in this table.

DM, diabetes mellitus; HTN, hypertension; N/A, not available.

^†Cutaneous reaction occurred 2 days after the first dose and recurred 2 days after the second dose.

^‡Fixed drug eruption occurred 14 days after the first dose and reappeared 14 days after the second dose.